Bafna Pharmaceuticals vs Nifty 50: Returns Compared
- September 9, 2026
- Posted by: Harsh Piplani
- Category: Market
Bafna Pharmaceuticals share price Rs 307.75 on NSE. Bafna Pharmaceuticals vs Nifty 50 over 1 year: +193.54% vs -4.61%. 52-week high Rs 318.50, low Rs 94.77.
Quick Answer
Bafna Pharmaceuticals vs Nifty 50 shows Bafna Pharmaceuticals ahead of the benchmark on a one-year view, gaining +193.54% against the Nifty 50’s -4.61%. Over the longer term the stock has also stayed ahead of the index, a pattern that reflects its underlying business momentum rather than a single quarter’s swing. Investors comparing the two should also weigh Bafna Pharmaceuticals’s trading liquidity, valuation and sector context rather than relying on returns alone.
Bafna Pharmaceuticals vs Nifty 50 is a comparison that looks different depending on the time frame chosen. Bafna Pharmaceuticals trades on the NSE under the symbol BAFNAPH, and its 1M return of +17.06% compares with the Nifty 50’s -3.66% over the same period.
The Bafna Pharmaceuticals vs Nifty 50 comparison matters because Bafna Pharmaceuticals is a single stock exposed to its own sector and company-specific developments, while the Nifty 50 spreads risk across 50 large companies. This article lines up Bafna Pharmaceuticals share price performance against the Nifty 50 across 1 month, 3 months, 6 months, 1 year, 3 years, 5 years, using NSE closing data.
Click Here – Get Free Investment Predictions
Bafna Pharmaceuticals vs Nifty 50: Performance at a Glance
The table below sets out Bafna Pharmaceuticals vs Nifty 50 performance across the available time frames, measured from NSE closing prices up to 9 September 2026.
| Time Frame | Bafna Pharmaceuticals Return | Nifty 50 Return | Difference |
|---|---|---|---|
| 1 Month | +17.06% | -3.66% | +20.72% pp |
| 3 Months | +122.22% | +0.46% | +121.76% pp |
| 6 Months | +184.72% | -5.53% | +190.25% pp |
| 1 Year | +193.54% | -4.61% | +198.15% pp |
| 3 Years | +215.97% | +20.86% | +195.1% pp |
| 5 Years | +137.1% (Bafna Pharmaceuticals) | +35.35% (Nifty 50) | +101.75% pp |
On the Bafna Pharmaceuticals vs Nifty 50 scorecard, Bafna Pharmaceuticals has stayed ahead of the index over the most recent one-year window. Over the longer term the stock has also stayed ahead of the index, a pattern that reflects its underlying business momentum rather than a single quarter’s swing.
Check the Univest Screener for live Bafna Pharmaceuticals and Nifty 50 data
Why the Bafna Pharmaceuticals vs Nifty 50 Gap Exists
Bafna Pharmaceuticals’s stock can move quite differently from the Nifty 50 because it carries concentrated exposure to its own sector and business cycle, unlike the index which blends 50 companies across banking, IT, energy and consumer sectors. This is the main driver of the gap seen in the Bafna Pharmaceuticals vs Nifty 50 return table above.
A second factor behind the Bafna Pharmaceuticals vs Nifty 50 divergence is valuation and trading liquidity. Company-specific news, quarterly results and sector sentiment can move Bafna Pharmaceuticals’s price sharply in either direction over short periods, while the Nifty 50’s return reflects the blended earnings trajectory of its constituents and is far less exposed to any single stock’s swings.
Download the Univest iOS App or Univest Android App to track Bafna Pharmaceuticals and Nifty 50 live on the go.
Bafna Pharmaceuticals vs Nifty 50: Has Bafna Pharmaceuticals Beaten the Benchmark?
Bafna Pharmaceuticals has beaten the Nifty 50 over the past year, gaining +193.54% against the index’s -4.61% over the same period.
Risks of the Bafna Pharmaceuticals vs Nifty 50 Comparison
Reading too much into a Bafna Pharmaceuticals vs Nifty 50 comparison has real limitations that investors should weigh before drawing conclusions. Bafna Pharmaceuticals carries concentrated business and sector risk that a diversified index does not, and its trading volumes and price swings can differ meaningfully from the Nifty 50’s more liquid, blended profile. A stock’s 52-week range of Rs 94.77 to Rs 318.50 also shows the kind of volatility that a single-stock investment carries relative to a broad index.
Conclusion
Bafna Pharmaceuticals vs Nifty 50 highlights how a single stock’s return path can differ from a diversified benchmark over different time horizons. Investors weighing the Bafna Pharmaceuticals vs Nifty 50 record should factor in Bafna Pharmaceuticals’s volatility, liquidity and sector concentration alongside its return history, and consult a SEBI-registered advisor before making an allocation decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Has Bafna Pharmaceuticals outperformed the Nifty 50 in the last year?
Ans. Yes. Bafna Pharmaceuticals gained +193.54% over the past year while the Nifty 50 returned -4.61% over the same period, based on NSE closing prices to 9 September 2026.
How does Bafna Pharmaceuticals vs Nifty 50 look over 5 years?
Ans. Over five years Bafna Pharmaceuticals has returned +137.1% compared with the Nifty 50’s +35.35%, so in the Bafna Pharmaceuticals vs Nifty 50 comparison the stock has been ahead over this longer horizon.
What is the Bafna Pharmaceuticals share price today compared to Nifty 50?
Ans. Bafna Pharmaceuticals share price stood at Rs 307.75 on NSE, while the Nifty 50 traded at 23,490.45 based on the same closing data window.
What is the 52-week high and low of Bafna Pharmaceuticals?
Ans. Bafna Pharmaceuticals’s 52-week high is Rs 318.50 and its 52-week low is Rs 94.77, based on NSE data.
Why does Bafna Pharmaceuticals show bigger price swings than the Nifty 50?
Ans. Bafna Pharmaceuticals carries concentrated exposure to its own sector and business cycle, while the Nifty 50 spreads risk across 50 large companies, so company-specific news moves Bafna Pharmaceuticals’s price more sharply than the diversified index, a key reason the Bafna Pharmaceuticals vs Nifty 50 return gap varies across time frames.
Is Bafna Pharmaceuticals a good long-term investment compared to a Nifty 50 index fund?
Ans. Bafna Pharmaceuticals’s suitability depends on an investor’s risk appetite, since single-stock exposure carries higher concentration risk than a diversified Nifty 50 index fund; long-term investors should weigh the Bafna Pharmaceuticals vs Nifty 50 return history alongside the company’s fundamentals and consult a SEBI-registered advisor.
